A Single-center, Randomized, Controlled, Open-label Study to Investigate the Nicotine Pharmacokinetic Profiles and Subjective Effects of Four Variants of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Background-corrected Maximum Plasma Concentration [Cmax]
研究概览
简要总结
This is a single-center, randomized, controlled, open-label, cross-over study in healthy smoking subjects to investigate the nicotine pharmacokinetic (PK) profiles of 4 variants of Nicotine pouch 1.0 compared to marketed Velo - Nicotine Pouch (NP) and Zyn-NP. In addition, pharmacodynamic (PD) effects will be evaluated to provide further insights on Nicotine pouch 1.0 product acceptance and abuse liability. The study will be conducted with 3 periods and 6 sequences in a Williams design (cross-over).
详细描述
Study Title:
Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers
Who carried out the research? This research was sponsored and funded by Philip Morris Products S.A.
What public involvement there was in the study? The study recruited 31 healthy adults who were currently smoking.
Where and when the study took place The study was conducted at a clinical trial facility managed by a contract research organization in Belfast, Northern Ireland, from March 15th to August 18th 2022.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Main Inclusion Criteria:
- •Subject has smoked continuously for at least the last 3 years prior to the Screening visit.
- •Subject has smoked ≥ 10 commercially available cigarettes per day for 4 weeks prior to Screening Visit and Admission. Smoking status will be verified based on a urinary cotinine test (cotinine ≥ 500 ng/mL).
- •Subject does not plan to quit using tobacco and/or nicotine products within the next 3 months.
- •Smoking, healthy subject as judged by the Investigator or designee based on available assessments from the Screening period.
排除标准
- •As per the Investigator's judgment, the subject cannot participate in the study for any reason other than medical.
- •Subject is legally incompetent, or physically or mentally incapable of giving consent.
- •Subject has a clinically relevant disease that requires medication, which as per the judgment of the Investigator would jeopardize the safety of the subject.
- •Subject has donated or received whole blood or blood products within 30 days prior to Screening Visit.
- •Subject has a BMI < 18.5 kg/m2 or > 32.0 kg/m2 (Europe) or > 35.0 kg/m2 (USA).
- •For women only: subject is pregnant (does not have negative pregnancy test at Screening Visit and at Admission) or is breastfeeding.
研究组 & 干预措施
NP-3
Nicotine Pouch 1.0 (variant NP-3)
干预措施: NP-3 (Other)
Zyn-NP
Zyn® Cool Mint Mini Dry
干预措施: Zyn-NP (Other)
Velo-NP
Velo® Ice Cool
干预措施: NP-3 (Other)
NP-4
Nicotine Pouch 1.0 (variant NP-4)
干预措施: NP-3 (Other)
NP-1
Nicotine Pouch 1.0 (variant NP-1)
干预措施: NP-2 (Other)
NP-1
Nicotine Pouch 1.0 (variant NP-1)
干预措施: Velo-NP (Other)
Zyn-NP
Zyn® Cool Mint Mini Dry
干预措施: Velo-NP (Other)
NP-1
Nicotine Pouch 1.0 (variant NP-1)
干预措施: Zyn-NP (Other)
NP-2
Nicotine Pouch 1.0 (variant NP-2)
干预措施: NP-2 (Other)
NP-2
Nicotine Pouch 1.0 (variant NP-2)
干预措施: Velo-NP (Other)
NP-2
Nicotine Pouch 1.0 (variant NP-2)
干预措施: Zyn-NP (Other)
NP-3
Nicotine Pouch 1.0 (variant NP-3)
干预措施: NP-2 (Other)
NP-3
Nicotine Pouch 1.0 (variant NP-3)
干预措施: Velo-NP (Other)
NP-3
Nicotine Pouch 1.0 (variant NP-3)
干预措施: Zyn-NP (Other)
NP-4
Nicotine Pouch 1.0 (variant NP-4)
干预措施: NP-2 (Other)
NP-4
Nicotine Pouch 1.0 (variant NP-4)
干预措施: Velo-NP (Other)
NP-4
Nicotine Pouch 1.0 (variant NP-4)
干预措施: Zyn-NP (Other)
Velo-NP
Velo® Ice Cool
干预措施: NP-2 (Other)
Velo-NP
Velo® Ice Cool
干预措施: Velo-NP (Other)
Velo-NP
Velo® Ice Cool
干预措施: Zyn-NP (Other)
Zyn-NP
Zyn® Cool Mint Mini Dry
干预措施: NP-2 (Other)
NP-3
Nicotine Pouch 1.0 (variant NP-3)
干预措施: NP-1 (Other)
NP-1
Nicotine Pouch 1.0 (variant NP-1)
干预措施: NP-4 (Other)
Zyn-NP
Zyn® Cool Mint Mini Dry
干预措施: NP-4 (Other)
Zyn-NP
Zyn® Cool Mint Mini Dry
干预措施: NP-3 (Other)
Zyn-NP
Zyn® Cool Mint Mini Dry
干预措施: NP-1 (Other)
Velo-NP
Velo® Ice Cool
干预措施: NP-4 (Other)
Velo-NP
Velo® Ice Cool
干预措施: NP-1 (Other)
NP-4
Nicotine Pouch 1.0 (variant NP-4)
干预措施: NP-4 (Other)
NP-4
Nicotine Pouch 1.0 (variant NP-4)
干预措施: NP-1 (Other)
NP-3
Nicotine Pouch 1.0 (variant NP-3)
干预措施: NP-4 (Other)
NP-2
Nicotine Pouch 1.0 (variant NP-2)
干预措施: NP-4 (Other)
NP-2
Nicotine Pouch 1.0 (variant NP-2)
干预措施: NP-3 (Other)
NP-2
Nicotine Pouch 1.0 (variant NP-2)
干预措施: NP-1 (Other)
NP-1
Nicotine Pouch 1.0 (variant NP-1)
干预措施: NP-3 (Other)
NP-1
Nicotine Pouch 1.0 (variant NP-1)
干预措施: NP-1 (Other)
结局指标
主要结局
Background-corrected Maximum Plasma Concentration [Cmax]
时间窗: T0 = start of product use. Blood was drawn 5 minutes prior to T0, and then 5, 10, 15, 20, 25, 30, 35, 40 minutes, 1, 3, and 6 hours after T0, on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon).
To measure the background-corrected maximum plasma concentration \[Cmax\] of 4 variants of NP 1.0 nicotine pouches compared to Velo-NP and Zyn-NP in healthy smokers from a 30 minutes product use period.
Background-corrected Time to the Maximum Concentration [Tmax]
时间窗: T0 = start of product use. Blood was drawn 5 minutes prior to T0, and then 5, 10, 15, 20, 25, 30, 35, 40 minutes, 1, 3, and 6 hours after T0, on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon).
To measure the background-corrected time to the maximum concentration \[Tmax\] of 4 variants of NP 1.0 nicotine pouches compared to Velo-NP and Zyn-NP in healthy smokers from a 30 minutes product use period.
Area Under the Background-corrected Concentration-time Curve (AUC) From Start of Product Use, Extrapolated to Infinity (AUC Infinity)
时间窗: T0 = start of product use. Blood was drawn 5 minutes prior to T0, and then 5, 10, 15, 20, 25, 30, 35, 40 minutes, 1, 3, and 6 hours after T0, on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon).
To measure the area under the background-corrected concentration-time curve (AUC) from start of product use of 4 variants of NP 1.0 nicotine pouches compared to Velo-NP and Zyn-NP in healthy smokers from a 30 minutes product use period.
次要结局
- Score of Cigarette Craving by the Visual Analog Scale (VAS)-Craving Assessment(Measured before, and up to 6 hours post-product use on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon))
- Score of "in the Moment" Product Liking by the VAS-liking Assessment(Measured up to 1 hour post-product use on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon))
- Score of Overall Product Liking by the VAS-liking Assessment(Measured after 30 minutes product use on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon))
- Score of Product Satisfaction by the VAS-satisfaction Assessment(Measured on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon))
- Score of Product Intention to Use Again by the VAS-intention to Use Again Assessment(Measured on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon))